Lancashire and South Cumbria
Formulary
Formulary
6 Endocrine system
06-04-02 Anti-androgens
| Cyproterone Acetate |
|
Formulary
|
Tablets 50mg For indications other than oncology |
 MHRA Drug Safety Update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma |
|
| Finasteride |
|
Formulary
|
tablets 5mg Finasteride is the preferred 5α-reductase inhibitor for Benign Prostatic Hyperplasia (BPH). |
|
LSCMMG: Finasteride MHRA: Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment) |
|
|
Links
- Diabetes UK: Diabetes when you’re unwell
LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Hormone Therapy in Gender Dysphoria Prescribing Information Sheet
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG Shared care Guideline - testosterone
- LSCMMG Shared Care Guideline - testosterone
- LSCMMG: Diabetes - Choice of Safety Pen Needles and Lancets
- LSCMMG: Diabetes - Pen Needles/Lancets
- LSCMMG: Diabetes - Position Statement Safety Needles and Safety Lancets
- LSCMMG: Diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes
- LSCMMG: Diabetes: Recommended meters, strips and devices
- LSCMMG: Finasteride
LSCMMG: GLP-1 patient contract- LSCMMG: Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus
- LSCMMG: SHARED CARE GUIDELINE: Testosterone For hypogonadism due to testosterone deficiency in adult men
- LSCMMG: SHARED CARE GUIDELINE: Testosterone For hypogonadism due to testosterone deficiency in adult men
- LSCMMG: Testosterone (Testim® ) NMR
- LSCMMG: Testosterone (transdermal) NMR
- LSCMMG: Trans Female Gender Dysphoria Information Sheet
- LSCMMG: Trans Male Gender Dysphoria Information Sheet
- LSCMMG:Testosterone (transdermal) As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective shared care guideline
- MHRA Drug Safety update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA Drug Safety Update June 2020: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA: Diabetes and driving
- MHRA: Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)
- MHRA: Topical testosterone (Testogel): risk of harm to children following accidental exposure
- MHRA: Topical testosterone (Testogel): risk of harm to children following accidental exposure
- NHSE guidance to primary care about unregulated providers who supply hormone medications to children and young people for gender incongruence
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- SHARED CARE GUIDELINE :As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective